Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

Prior treatment

• Participants whose planned surgery at enrollment is a wedge resection
• Previously infected or tested positive for human immunodeficiency virus.

Other illness

• Participants contraindicated for surgical intervention due to comorbid conditions
• Participants who are allergic to study intervention.
• Known active hepatitis infection, positive HCV antibody, HBsAg or HBV core antibody (anti-HBc), at screening.

Lab values

• Known EGFR mutation or ALK translocation

Other

• Unresectable NSCLC confirmed by MDT evaluation at baseline
• Stage IIIC patients
• Participants with more than one primary tumour.
• Female participants who are pregnant or breastfeeding.
• Judgement by the investigator that the participant should not participate in the study.

• Deemed resectable or borderline resectable at baseline, confirmed by MDT evaluation at diagnosis.
• Previously untreated and pathologically confirmed Stage IIB to select \[i.e.N2\] Stage IIIB by AJCC v8.
• Nodal status confirmed with whole body FDG-PET and biopsy via endobronchial ultrasound, mediastinoscopy, or thoracoscopy.
• Mandatory brain MRI.
• EGFR and ALK wild-type.
• Medically operable: adequate cardiac and lung function to undergo resection.
• Participant must be ≥ 18 years, at the time of screening.
• Histologically or cytologically documented NSCLC.
• Minimum life expectancy of 12 weeks.
• Minimum body weight of 30 kg.
• Male and female participants must be willing to use acceptable methods of contraception.
• Female participants of childbearing potential must have negative pregnancy test.